N R Chu

Summary

Publications

  1. pmc Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7
    N R Chu
    StressGen Biotechnologies Corporation, Victoria, B C, Canada, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Clin Exp Immunol 121:216-25. 2000
  2. pmc Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7
    N R Chu
    StressGen Biotechnologies Corp, Victoria, BC, Canada
    Cell Stress Chaperones 5:401-5. 2000
  3. ncbi request reprint Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease
    N Randall Chu
    StressGen Biotechnologies Corp, 350 4243 Glanford Ave, Victoria, BC, Canada, V8Z 4B9
    Expert Opin Biol Ther 3:477-86. 2003
  4. ncbi request reprint CoVal fusions: a therapeutic vaccine platform using heat shock proteins to treat chronic viral infection and cancer
    J R Neefe
    Stressgen Biotechnologies, Collegeville, PA, USA
    Dev Biol (Basel) 116:193-200; discussion 229-36. 2004
  5. ncbi request reprint CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer
    Dylan Daniel
    Department of Biochemistry, Diabetes Center and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 0534, USA
    Cancer Res 65:2018-25. 2005

Collaborators

  • T C Wu
  • J R Neefe
  • Dylan Daniel
  • Christopher Chiu
  • Douglas Hanahan
  • Lee A Mizzen
  • Masahiro Inoue
  • Enrico Giraudo

Detail Information

Publications5

  1. pmc Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7
    N R Chu
    StressGen Biotechnologies Corporation, Victoria, B C, Canada, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Clin Exp Immunol 121:216-25. 2000
    ..These studies extend previous observations on the induction of cytotoxic T lymphocytes by hsp fusion proteins and are consistent with the clinical application of hspE7 as an immunotherapy for human cervical and anal dysplasia and cancer...
  2. pmc Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7
    N R Chu
    StressGen Biotechnologies Corp, Victoria, BC, Canada
    Cell Stress Chaperones 5:401-5. 2000
    ..These studies extend previous observations on the induction of CTL by Hsp fusion proteins and are consistent with the clinical application of HspE7 as an immunotherapy for human cervical and anal dysplasia and cancer...
  3. ncbi request reprint Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease
    N Randall Chu
    StressGen Biotechnologies Corp, 350 4243 Glanford Ave, Victoria, BC, Canada, V8Z 4B9
    Expert Opin Biol Ther 3:477-86. 2003
    ..Immunisation approaches such as adjuvanted peptides, virus-like particles and fusion constructs are discussed. Specifically, chimaeric molecules comprised of mycobacterial heat-shock proteins (Hsps) and HPV16 E7 appear promising...
  4. ncbi request reprint CoVal fusions: a therapeutic vaccine platform using heat shock proteins to treat chronic viral infection and cancer
    J R Neefe
    Stressgen Biotechnologies, Collegeville, PA, USA
    Dev Biol (Basel) 116:193-200; discussion 229-36. 2004
    ..Potential targets include hepatitis B, herpes simplex, hepatitis C, and human immunodeficiency virus...
  5. ncbi request reprint CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer
    Dylan Daniel
    Department of Biochemistry, Diabetes Center and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143 0534, USA
    Cancer Res 65:2018-25. 2005
    ..Thus, an HPV16 E7 immunogen holds promise for noninvasive treatment and prevention of human cervical cancer...